Know Cancer

forgot password

A Phase II/III Study of Immunomodulation After High Dose Myeloablative Therapy With Autologous Stem Cell Rescue for Refractory/Relapsed Hodgkin Disease

Phase 2/Phase 3
30 Years
Not Enrolling

Thank you

Trial Information

A Phase II/III Study of Immunomodulation After High Dose Myeloablative Therapy With Autologous Stem Cell Rescue for Refractory/Relapsed Hodgkin Disease



- Phase II

- Determine the feasibility and toxicity of immunotherapy comprising cyclosporine,
interferon gamma, and interleukin-2 after high-dose myeloablative chemotherapy
with autologous stem cell transplantation (ASCT) in patients with refractory or
relapsed Hodgkin's lymphoma.

- Phase III

- Compare the event-free and overall survival of patients treated with vs without
this immunotherapy regimen.


- Determine the event-free and overall survival rates, toxic effects, and response rates
to reinduction chemotherapy followed by hyperfractionated involved-field radiotherapy,
high-dose chemotherapy comprising carmustine, etoposide, cytarabine, and melphalan, and
ASCT in these patients.

- Correlate tumor biologic characteristics with response in patients treated with these

- Determine the effectiveness of this immunotherapy regimen in producing autologous
graft-vs-host disease (GVHD) and auto-reactive cytotoxic T-lymphocyte activity in these

- Correlate greater levels of autologous GVHD and in vitro cytolytic activity with
improved event-free and overall survival in patients treated with these regimens.

- Determine whether treatment with immunotherapy can overcome the negative prognostic
significance of p53 mutation and high serum levels of interleukin-10 and interleukin-2
receptor in these patients.

- Determine the genotoxicity of retrieval therapy and the incidence of hypermutability by
longitudinal genotoxic biomonitoring in these patients.

- Correlate HLA class II invariant peptide (CLIP) expression in tumor cells with improved
event-free and overall survival in patients treated with immunotherapy regimen.

OUTLINE: This is a nonrandomized, multicenter phase II study followed by a randomized,
multicenter phase III study. Patients are stratified according to study phase (II vs III).

Patients receive 2 courses of salvage induction therapy on COG-AHOD00P1 or equivalent.
Within 2-5 weeks after completion of salvage induction therapy, patients receive protocol

- Phase II: All patients receive the following treatment:

- Hyperfractionated involved-field radiotherapy: Patients who have completed prior
salvage induction therapy and have not received full tissue tolerance from prior
radiotherapy may receive hyperfractionated involved-field radiotherapy twice daily
for 7 days.

- High-dose preparative regimen: Beginning within 7 days after radiotherapy,
patients receive carmustine IV over 3 hours on day -6; etoposide IV over 1 hour
and cytarabine IV over 1 hour on days -5 to -2; and melphalan IV over 30 minutes
on day -1.

- Autologous stem cell transplantation: Patients undergo autologous bone marrow or
peripheral blood stem cell transplantation on day 0. Patients then receive
filgrastim (G-CSF) subcutaneously (SC) or IV beginning on day 1 and continuing
until blood counts recover.

- Immunotherapy: Patients receive cyclosporine IV twice daily beginning on day 0 and
continuing until the completion of the course of interferon gamma and
interleukin-2. When sufficiently recovered, patients also receive interferon gamma
SC every other day for 10 doses. Beginning 2 days after the start of interferon
gamma, patients also receive interleukin-2 SC once daily for 18 days.

- Phase III: Patients who respond to prior salvage induction therapy are randomized to 1
of 2 treatment arms. Patients who have progressive disease after 2 courses of prior
salvage induction therapy are assigned to arm I.

- Arm I: Patients receive treatment as in phase II.

- Arm II: Patients receive treatment as in phase II without immunotherapy. In both
phases, treatment continues in the absence of disease progression or unacceptable

Patients are followed at 1 year.

PROJECTED ACCRUAL: A total of 156 patients (25 for phase II and 131 for phase III) will be
accrued for this study within 5.4 years.

Inclusion Criteria


- Diagnosis of Hodgkin's lymphoma

- Histologically confirmed at original diagnosis AND at relapse or disease

- Relapsed or refractory to conventional therapy

- No recurrence without B symptoms or bulky disease at least 1 year after completion of
minimal systemic therapy defined by either of the following:

- Stage IA/IIA with nodal disease previously treated with radiotherapy only

- Stage IA/IIA with nodal disease previously treated with less than 3 courses of
standard dose chemotherapy

- Concurrently enrolled on the COG-AHOD00P1 salvage chemotherapy study OR received
other appropriate salvage therapy (e.g., ifosfamide and vinorelbine)



- Under 30

Performance status

- ECOG 0-2 (for adults)

- Lansky 50-100% (for children)

Life expectancy

- At least 2 months


- Absolute neutrophil count at least 500/mm^3


- Bilirubin no greater than 1.5 times normal

- SGPT less than 2.5 times normal


- Creatinine no greater than 1.5 times normal OR

- Creatinine clearance or radioisotope glomerular filtration rate at least 70
mL/min/1.73 m^2


- Shortening fraction at least 27% by echocardiogram OR

- Ejection fraction at least 50% by MUGA


- No evidence of dyspnea at rest

- No exercise intolerance

- DLCO at least 50% (patients 8 years of age and over)


- Not pregnant or nursing

- Negative pregnancy test

- No concurrent serious illness


Biologic therapy

- Recovered from prior immunotherapy

- At least 1 week since prior antineoplastic biologic agents

- More than 1 week since prior growth factors

- No prior stem cell transplantation

- No other concurrent immunomodulating agents


- See Disease Characteristics

- More than 2 weeks since prior myelosuppressive chemotherapy (4 weeks for
nitrosoureas) and recovered

- No other concurrent anticancer chemotherapy

Endocrine therapy

- No concurrent steroids, including dexamethasone as an antiemetic


- See Disease Characteristics

- Recovered from prior radiotherapy


- Not specified


- No concurrent participation in another COG therapeutic study

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Incidence of death, excluding death due to disease, during the period of time from day 0 (transplant) through day 100 post transplant

Outcome Description:

Death, excluding death due to disease, during the period of time from Day 0 (transplant) through Day 100 post transplant.

Outcome Time Frame:

Day 0 (transplant) through Day 100 (Post transplant)

Safety Issue:


Principal Investigator

Allen R. Chen, MD, PhD, MHS

Investigator Role:

Study Chair

Investigator Affiliation:

Sidney Kimmel Comprehensive Cancer Center


United States: Federal Government

Study ID:




Start Date:

November 2003

Completion Date:

Related Keywords:

  • Lymphoma
  • recurrent adult Hodgkin lymphoma
  • recurrent/refractory childhood Hodgkin lymphoma
  • Hodgkin Disease
  • Lymphoma



Roswell Park Cancer Institute Buffalo, New York  14263
Mayo Clinic Cancer Center Rochester, Minnesota  55905
Emory University Hospital - Atlanta Atlanta, Georgia  30322
Indiana University Cancer Center Indianapolis, Indiana  46202-5265
Barbara Ann Karmanos Cancer Institute Detroit, Michigan  48201
University of Mississippi Medical Center Jackson, Mississippi  39216-4505
Hurley Medical Center Flint, Michigan  48503
University of Texas Health Science Center at San Antonio San Antonio, Texas  78284-7811
Midwest Children's Cancer Center Milwaukee, Wisconsin  53226
Van Elslander Cancer Center at St. John Hospital and Medical Center Grosse Pointe Woods, Michigan  48236
Penn State Cancer Institute at Milton S. Hershey Medical Center Hershey, Pennsylvania  17033-0850
Marshfield Clinic - Marshfield Center Marshfield, Wisconsin  54449
Massachusetts General Hospital Cancer Center Boston, Massachusetts  02114
New York Medical College Valhalla, New York  10595
University of Miami Sylvester Comprehensive Cancer Center Miami, Florida  33136
Long Island Cancer Center at Stony Brook University Hospital Stony Brook, New York  11790-7775
CCOP - Scott and White Hospital Temple, Texas  76508
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland  21231-2410
Children's Hospital of Orange County Orange, California  92668
Children's National Medical Center Washington, District of Columbia  20010-2970
Children's Mercy Hospital Kansas City, Missouri  64108
Children's Hospital of Pittsburgh Pittsburgh, Pennsylvania  15213
Nemours Children's Clinic Jacksonville, Florida  32207
Miami Children's Hospital Miami, Florida  33155-4069
All Children's Hospital St. Petersburg, Florida  33701
Children's Memorial Hospital - Chicago Chicago, Illinois  60614
Children's Hospital of New Orleans New Orleans, Louisiana  70118
St. Jude Children's Research Hospital Memphis, Tennessee  38105-2794
Cook Children's Medical Center - Fort Worth Fort Worth, Texas  76104
Phoenix Children's Hospital Phoenix, Arizona  85016-7710
Southern Illinois University School of Medicine Springfield, Illinois  62794-9658
Kosair Children's Hospital Louisville, Kentucky  40202-3830
Children's Medical Center - Dayton Dayton, Ohio  45404
Texas Tech University Health Sciences Center School of Medicine Amarillo, Texas  79106
Covenant Children's Hospital Lubbock, Texas  79410
Children's Hospital of the King's Daughters Norfolk, Virginia  23507
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences Little Rock, Arkansas  72205
Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center Kansas City, Kansas  66160-7353
Fairview University Medical Center - University Campus Minneapolis, Minnesota  55455
Comprehensive Cancer Center at University of Alabama at Birmingham Birmingham, Alabama  35294
Children's Hospital and Research Center - Oakland Oakland, California  94609-1809
Kaiser Permanente Medical Center - Oakland Sacramento, California  95825
University of Florida Shands Cancer Center Gainesville, Florida  32610-0232
St. Joseph's Cancer Institute at St. Joseph's Hospital Tampa, Florida  33607
Kaplan Cancer Center at St. Mary's Medical Center West Palm Beach, Florida  33407
St. Vincent Indianapolis Hospital Indianapolis, Indiana  46260
C.S. Mott Children's Hospital at University of Michigan Ann Arbor, Michigan  48109-0238
Spectrum Health Cancer Care - Butterworth Campus Grand Rapids, Michigan  49503-2560
Hackensack University Medical Center Cancer Center Hackensack, New Jersey  07601
Mount Sinai Medical Center New York, New York  10029
SUNY Upstate Medical University Hospital Syracuse, New York  13210
Cincinnati Children's Hospital Medical Center Cincinnati, Ohio  45229-3039
Rainbow Babies and Children's Hospital Cleveland, Ohio  44106-5000
Hollings Cancer Center at Medical University of South Carolina Charleston, South Carolina  29425
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas Dallas, Texas  75390
Methodist Children's Hospital of South Texas San Antonio, Texas  78229-3993
St. Vincent Hospital Regional Cancer Center Green Bay, Wisconsin  54307-3508
Jonsson Comprehensive Cancer Center at UCLA Los Angeles, California  90095-1781
Alfred I. duPont Hospital for Children Wilmington, Delaware  19803
Children's Hospital of Minnesota - Minneapolis Minneapolis, Minnesota  55404